These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37210771)

  • 1. Immunohistochemical expression of PRAME is a marker of poor prognosis in uveal melanoma: A clinico-pathologic and immunohistochemical study on a series of 85 cases.
    Broggi G; Failla M; Russo A; Longo A; Palicelli A; Zanelli M; Lombardo C; Loreto C; Merolla F; Di Crescenzo RM; Ilardi G; Varricchio S; Staibano S; Caltabiano R
    Pathol Res Pract; 2023 Jul; 247():154543. PubMed ID: 37210771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
    Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
    Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRAME Expression in Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of PRAME immunohistochemistry reveals lower expression in pediatric melanoma compared to adult melanoma.
    Forchhammer S; Aebischer V; Lenders D; Seitz CM; Schroeder C; Liebmann A; Abele M; Wild H; Bien E; Krawczyk M; Schneider DT; Brecht IB; Flatz L; Hahn M
    Pigment Cell Melanoma Res; 2024 Jul; 37(4):453-461. PubMed ID: 38509752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
    Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
    JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
    Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
    J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
    Schefler AC; Koca E; Bernicker EH; Correa ZM
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRAME Updated: Diagnostic, Prognostic, and Therapeutic Role in Skin Cancer.
    Cassalia F; Danese A; Tudurachi I; Federico S; Zambello A; Guidotti A; Franceschin L; Bolzon A; Naldi L; Belloni Fortina A
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
    Kumar N; Singh MK; Singh L; Lomi N; Meel R; Pushker N; Sen S; Kashyap S
    Hum Cell; 2023 Jan; 36(1):342-352. PubMed ID: 36282437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.
    Gelmi MC; Gezgin G; van der Velden PA; Luyten GPM; Luk SJ; Heemskerk MHM; Jager MJ
    Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):36. PubMed ID: 38149971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
    Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
    Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRAME Expression in Challenging Dermal Melanocytic Neoplasms and Soft Tissue Tumors With Melanocytic Differentiation.
    Kline N; Menge TD; Hrycaj SM; Andea AA; Patel RM; Harms PW; Chan MP; Bresler SC
    Am J Dermatopathol; 2022 Jun; 44(6):404-410. PubMed ID: 34991102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRAME expression in 155 cases of metastatic melanoma.
    Gradecki SE; Slingluff CL; Gru AA
    J Cutan Pathol; 2021 Apr; 48(4):479-485. PubMed ID: 32939793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
    Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
    Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.
    Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR
    J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases.
    Lo Bello G; Pini GM; Giagnacovo M; Patriarca C
    Pathol Res Pract; 2023 Nov; 251():154915. PubMed ID: 37913637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME expression in melanocytic lesions of the nail.
    Parra O; Linos K; Li Z; Yan S
    J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
    Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
    Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRAME is a useful marker for the differential diagnosis of melanocytic tumours and histological mimics.
    Chen YP; Zhang WW; Qiu YT; Ke LF; Chen H; Chen G
    Histopathology; 2023 Jan; 82(2):285-295. PubMed ID: 36200756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.